17 18

Cited 25 times in

Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial

Authors
 Jackie Bosch  ;  John W. Eikelboom  ;  Stuart J. Connolly  ;  Nancy Cook Bruns  ;  Vivian Lanius  ;  Fei Yuan MMath  ;  Frank Misselwitz  ;  Edmond Chen  ;  Rafael Diaz  ;  Marco Alings  ;  Eva M. Lonn  ;  Petr Widimsky  ;  Masatsugu Hori  ;  Alvaro Avezum  ;  Leopoldo S. Piegas  ;  Deepak L. Bhatt  ;  Kelley R.H. Branch  ;  Jeffrey L. Probstfield  ;  Yan Liang  ;  Lisheng Liu  ;  Jun Zhu  ;  Aldo P. Maggioni  ;  Patricio Lopez-Jaramillo  ;  Martin O'Donnell  ;  Keith A.A. Fox  ;  Ajay Kakkar  ;  Alexander N. Parkhomenko  ;  Georg Ertl  ;  Stefan Störk  ;  Katalin Keltai  ;  Matyas Keltai  ;  Lars Ryden  ;  Gilles R. Dagenais  ;  Nana Pogosova  ;  Antonio L. Dans  ;  Fernando Lanas  ;  Patrick J. Commerford  ;  Christian Torp-Pedersen  ;  Tomasz J. Guzik  ;  Peter B. Verhamme  ;  Dragos Vinereanu  ;  Jae-Hyung Kim  ;  Jong-Won Ha  ;  Andrew M. Tonkin  ;  John D. Varigos  ;  Basil S. Lewis  ;  Camilo Felix  ;  Khalid Yusoff  ;  Philippe Gabriel Steg  ;  Victor Aboyans  ;  Kaj P. Metsarinne  ;  Sonia S. Anand  ;  Robert G. Hart  ;  Andre Lamy  ;  Paul Moayyedi  ;  Darryl P. Leong  ;  Mukul Sharma  ;  Salim Yusuf 
Citation
 Canadian Journal of Cardiology, Vol.33(8) : 1027-1035, 2017 
Journal Title
 Canadian Journal of Cardiology 
ISSN
 0828-282X 
Issue Date
2017
MeSH
Anticoagulants/therapeutic use* ; Cardiovascular Diseases/prevention & control* ; Humans ; Practice Guidelines as Topic* ; Randomized Controlled Trials as Topic/methods* ; Thrombolytic Therapy/standards*
Abstract
BACKGROUND: Long-term aspirin prevents vascular events but is only modestly effective. Rivaroxaban alone or in combination with aspirin might be more effective than aspirin alone for vascular prevention in patients with stable coronary artery disease (CAD) or peripheral artery disease (PAD). Rivaroxaban as well as aspirin increase upper gastrointestinal (GI) bleeding and this might be prevented by proton pump inhibitor therapy. METHODS: Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) is a double-blind superiority trial comparing rivaroxaban 2.5 mg twice daily combined with aspirin 100 mg once daily or rivaroxaban 5 mg twice daily vs aspirin 100 mg once daily for prevention of myocardial infarction, stroke, or cardiovascular death in patients with stable CAD or PAD. Patients not taking a proton pump inhibitor were also randomized, using a partial factorial design, to pantoprazole 40 mg once daily or placebo. The trial was designed to have at least 90% power to detect a 20% reduction in each of the rivaroxaban treatment arms compared with aspirin and to detect a 50% reduction in upper GI complications with pantoprazole compared with placebo. RESULTS: Between February 2013 and May 2016, we recruited 27,395 participants from 602 centres in 33 countries; 17,598 participants were included in the pantoprazole vs placebo comparison. At baseline, the mean age was 68.2 years, 22.0% were female, 90.6% had CAD, and 27.3% had PAD. CONCLUSIONS: COMPASS will provide information on the efficacy and safety of rivaroxaban, alone or in combination with aspirin, in the long-term management of patients with stable CAD or PAD, and on the efficacy and safety of pantoprazole in preventing upper GI complications in patients receiving antithrombotic therapy.
Files in This Item:
T201702690.pdf Download
DOI
10.1016/j.cjca.2017.06.001
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
하종원(Ha, Jong Won) ORCID logo https://orcid.org/0000-0002-8260-2958
Export
RIS (EndNote)
XLS (Excel)
XML
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/160571
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse